First-in-Class YAP/TEAD Inhibitor Demonstrates Early Efficacy Targeting Hippo Pathway OncLive, 11 Jan 2024 Ibiayi Dagogo-Jack, MD Investigators hope that first-in-class agents will combat dysfunction of the Hippo pathway, which…